prikaz prve stranice dokumenta Comparison of Verisyse and Veriflex Phakic Intraocular Lenses for Treatment of Moderate to High Myopia 36 Months after Surgery
Access restricted to all Croatian higher education institution's students and staff
Scientific paper - Original scientific paper
Comparison of Verisyse and Veriflex Phakic Intraocular Lenses for Treatment of Moderate to High Myopia 36 Months after Surgery
Seminars in Ophthalmology, 32 (2016), 6; 725-733. https://doi.org/10.3109/08820538.2016.1170163
Bohač, Maja; Antičić, Marija; Drača, Nataša; Kozomara, Bojan; Dekaris, Iva; Gabrić, Nikica; Patel, Sudi

Cite this document

Bohač, M., Antičić, M., Drača, N., Kozomara, B., Dekaris, I., Gabrić, N. & Patel, S. (2016). Comparison of Verisyse and Veriflex Phakic Intraocular Lenses for Treatment of Moderate to High Myopia 36 Months after Surgery. Seminars in Ophthalmology, 32. (6), 725-733. doi: 10.3109/08820538.2016.1170163

Bohač, Maja, et al. "Comparison of Verisyse and Veriflex Phakic Intraocular Lenses for Treatment of Moderate to High Myopia 36 Months after Surgery." Seminars in Ophthalmology, vol. 32, no. 6, 2016, pp. 725-733. https://doi.org/10.3109/08820538.2016.1170163

Bohač, Maja, Marija Antičić, Nataša Drača, Bojan Kozomara, Iva Dekaris, Nikica Gabrić and Sudi Patel. "Comparison of Verisyse and Veriflex Phakic Intraocular Lenses for Treatment of Moderate to High Myopia 36 Months after Surgery." Seminars in Ophthalmology 32, no. 6 (2016): 725-733. https://doi.org/10.3109/08820538.2016.1170163

Bohač, M., et al. (2016) 'Comparison of Verisyse and Veriflex Phakic Intraocular Lenses for Treatment of Moderate to High Myopia 36 Months after Surgery', Seminars in Ophthalmology, 32(6), pp. 725-733. doi: 10.3109/08820538.2016.1170163

Bohač M, Antičić M, Drača N, Kozomara B, Dekaris I, Gabrić N, and sur.. Comparison of Verisyse and Veriflex Phakic Intraocular Lenses for Treatment of Moderate to High Myopia 36 Months after Surgery. Seminars in Ophthalmology [Internet]. 2016 [cited 2024 November 23];32(6):725-733. doi: 10.3109/08820538.2016.1170163

M. Bohač, et al., "Comparison of Verisyse and Veriflex Phakic Intraocular Lenses for Treatment of Moderate to High Myopia 36 Months after Surgery", Seminars in Ophthalmology, vol. 32, no. 6, pp. 725-733, 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:827694. [Accessed: 23 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Comparison of Verisyse and Veriflex Phakic Intraocular Lenses for Treatment of Moderate to High Myopia 36 Months after Surgery
AuthorMaja Bohač
AuthorMarija Antičić
AuthorNataša Drača
AuthorBojan Kozomara
AuthorIva Dekaris
AuthorNikica Gabrić
AuthorSudi Patel
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Ophthalmology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Ophthalmology
Scientific / art field,
discipline and subdiscipline		INTERDISCIPLINARY AREAS OF KNOWLEDGE
Biotechnology in Biomedicine (natural science, biomedicine and healthcare, bioethics area
Abstract (english)
Abstract Purpose: To compare refractive stability, endothelial cell count (ECC), incidence of complications, and patients' satisfaction between a rigid Verisyse (group I, n = 198) and foldable Veriflex (group II, n = 212) phakic intraocular lenses (pIOL) over 36 months postop. Materials and methods: This was a retrospective study. Patients' satisfaction and incidence of photic phenomena were evaluated at one month and one year postop. Data were analyzed to determine difference between groups for astigmatism, mean spherical equivalent (MRSE), uncorrected (UDVA) and corrected (CDVA) monocular distance visual acuity, complication rate (acute and chronic), and ECC. Differences were considered statistically significant when p < 0.05. Results: Group II cases had significantly higher UDVA, CDVA, and lower astigmatism during the entire follow-up. There was no significant difference in mean MRSE or mean ECC postoperatively. In both groups, mean ECC reduced significantly at one month postop, followed by a gradual linear decline between 1 and 36 months of 22.4 cells/mm2/annum (group I) and 13.32 cells/mm2/annum (group II). Overall complication rates were ≤ 10% with no significant inter-group differences. Group I patients reported lower incidence of halos at one month but more problems with night vision at one year compared with group II. Overall satisfaction was high and total incidence of reported photic phenomena was low. Conclusion: Both Verisyse and Veriflex pIOLs are effective in correcting myopia. The Veriflex lens demonstrated better refractive outcome ; however, subclinical inflammation observed in the Veriflex group and potential influence of inflammation on ECC loss require further investigation.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleSeminars in Ophthalmology
Numberingvol. 32, no. 6, pp. 725-733
p-ISSN0882-0538
DOIhttps://doi.org/10.3109/08820538.2016.1170163
URN:NBNurn:nbn:hr:184:827694
Publication2016
Document URLhttp://bib.irb.hr/1149748
Type of resourceText
Access conditionsRestricted access
Terms of useLicence In copyright icon
Created on2022-02-14 09:53:22